{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:14:14Z","timestamp":1760148854197,"version":"build-2065373602"},"reference-count":28,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,6,11]],"date-time":"2023-06-11T00:00:00Z","timestamp":1686441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"ViiV Healthcare"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>The TANGO study (ClinicalTrials.gov, NCT03446573) demonstrated that switching to dolutegravir\/lamivudine (DTG\/3TC) was non-inferior to continuing tenofovir alafenamide-based regimens (TBR) through week 144. Retrospective baseline proviral DNA genotypes were performed for 734 participants (post-hoc analysis) to assess the impact of archived, pre-existing drug resistance on 144-week virologic outcomes by last on-treatment viral load (VL) and Snapshot. A total of 320 (86%) participants on DTG\/3TC and 318 (85%) on TBR had both proviral genotype data and \u22651 on-treatment post-baseline VL results and were defined as the proviral DNA resistance analysis population. Archived International AIDS Society\u2013USA major nucleoside reverse transcriptase inhibitor, non-nucleoside reverse transcriptase inhibitor, protease inhibitor, and integrase strand transfer inhibitor resistance-associated mutations (RAMs) were observed in 42 (7%), 90 (14%), 42 (7%), and 11 (2%) participants, respectively, across both groups; 469 (74%) had no major RAMs at baseline. M184V\/I (1%), K65N\/R (&lt;1%), and thymidine analogue mutations (2%) were infrequent. Through week 144, &gt;99% of participants on DTG\/3TC and 99% on TBR were virologically suppressed (last on-treatment VL &lt;50 copies\/mL) regardless of the presence of major RAMs. Results from the sensitivity analysis by Snapshot were consistent with the last available on-treatment VL. In TANGO, archived, pre-existing major RAMs did not impact virologic outcomes through week 144.<\/jats:p>","DOI":"10.3390\/v15061350","type":"journal-article","created":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T01:28:21Z","timestamp":1686533301000},"page":"1350","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Assessing the Virologic Impact of Archived Resistance in the Dolutegravir\/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144"],"prefix":"10.3390","volume":"15","author":[{"given":"Ruolan","family":"Wang","sequence":"first","affiliation":[{"name":"ViiV Healthcare, 406 Blackwell Street, Suite 300, Durham, NC 27701, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Wright","sequence":"additional","affiliation":[{"name":"GSK, 980 Great West Road, Brentford TW8 9GS, Middlesex, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parminder","family":"Saggu","sequence":"additional","affiliation":[{"name":"GSK, 980 Great West Road, Brentford TW8 9GS, Middlesex, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mounir","family":"Ait-Khaled","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, 980 Great West Road, Brentford TW8 9GS, Middlesex, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riya","family":"Moodley","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, 980 Great West Road, Brentford TW8 9GS, Middlesex, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris M.","family":"Parry","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, 980 Great West Road, Brentford TW8 9GS, Middlesex, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Lutz","sequence":"additional","affiliation":[{"name":"Infektiologikum, Stresemannallee 3, 60596 Frankfurt am Main, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Podzamczer","sequence":"additional","affiliation":[{"name":"Hospital Universitari de Bellvitge, Carrer de la Feixa Llarga, s\/n, 08907 L\u2019Hospitalet de Llobregat, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Moore","sequence":"additional","affiliation":[{"name":"Northside Clinic, 370 St Georges Rd, Fitzroy North, VIC 3068, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"G\u00f3rgolas Hern\u00e1ndez-Mora","sequence":"additional","affiliation":[{"name":"Jim\u00e9nez D\u00edaz Foundation University Hospital, Av. de los Reyes Cat\u00f3licos, 2, 28040 Madrid, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clifford","family":"Kinder","sequence":"additional","affiliation":[{"name":"AIDS Healthcare Foundation\u2013The Kinder Medical Group, 3661 S Miami Ave Suite 806, Miami, FL 33133, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Wynne","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, 406 Blackwell Street, Suite 300, Durham, NC 27701, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"van Wyk","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, 980 Great West Road, Brentford TW8 9GS, Middlesex, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Underwood","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, 406 Blackwell Street, Suite 300, Durham, NC 27701, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/QAI.0000000000002275","article-title":"Durable efficacy of dolutegravir plus lamivudine in antiretroviral treatment-naive adults with HIV-1 infection: 96-week results from the GEMINI-1 and GEMINI-2 randomized clinical trials","volume":"83","author":"Cahn","year":"2020","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/cid\/ciz1243","article-title":"Efficacy and safety of switching to dolutegravir\/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: Phase 3, randomized, noninferiority TANGO study","volume":"71","author":"Ajana","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/cid\/ciac036","article-title":"Efficacy and safety of switching to dolutegravir\/lamivudine versus continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: Results through week 144 from the phase 3, noninferiority TANGO randomized trial","volume":"75","author":"Osiyemi","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1093\/cid\/ciac130","article-title":"Efficacy and safety of switching to the 2-drug regimen dolutegravir\/lamivudine versus continuing a 3- or 4-drug regimen for maintaining virologic suppression in adults living with human immunodeficiency virus 1 (HIV-1): Week 48 results from the phase 3, noninferiority SALSA randomized trial","volume":"76","author":"Llibre","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_5","unstructured":"(2023, March 09). European AIDS Clinical Society Guidelines Version 11. Available online: https:\/\/www.eacsociety.org\/media\/guidelines-11.1_final_09-10.pdf."},{"key":"ref_6","unstructured":"(2023, March 23). Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV, Available online: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-arv."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jama.2022.22246","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society-USA Panel","volume":"329","author":"Gandhi","year":"2023","journal-title":"JAMA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S0140-6736(09)62041-9","article-title":"SWITCHMRK 1 and 2 investigators. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): Two multicentre, double-blind, randomised controlled trials","volume":"375","author":"Eron","year":"2010","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jcv.2018.04.001","article-title":"Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatment","volume":"104","author":"Armenia","year":"2018","journal-title":"J. Clin. Virol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/j.1468-1293.2012.01002.x","article-title":"Comparison of resistance mutation patterns in historical plasma HIV RNA genotypes with those in current proviral HIV DNA genotypes among extensively treated patients with suppressed replication","volume":"13","author":"Delaugerre","year":"2012","journal-title":"HIV Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1093\/jac\/dky130","article-title":"Dynamics of drug resistance-associated mutations in HIV-1 DNA reverse transcriptase sequence during effective ART","volume":"73","author":"Nouchi","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1093\/jac\/dkw146","article-title":"Usefulness of an HIV DNA resistance genotypic test in patients who are candidates for a switch to the rilpivirine\/emtricitabine\/tenofovir disoproxil fumarate combination","volume":"71","author":"Allavena","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1128\/JVI.79.8.5203-5210.2005","article-title":"In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA","volume":"79","author":"Sharkey","year":"2005","journal-title":"J. Virol."},{"key":"ref_14","first-page":"828","article-title":"HIV-1 DNA resistance testing informs the successful switch to a single tablet regimen","volume":"12","author":"Rodriguez","year":"2020","journal-title":"J. AIDS Clin. Res."},{"key":"ref_15","first-page":"559","article-title":"2022 update of the drug resistance mutations in HIV-1","volume":"30","author":"Wensing","year":"2022","journal-title":"Top. Antivir. Med."},{"key":"ref_16","unstructured":"Underwood, M., Osiyemi, O., Rubio, R., Hocqueloux, L., Porteiro, N., Degen, O., Oyee, J., Horton, J., Parry, C., and Wang, R. (2022, January 12\u201316). Archived Resistance and Response to <40 c\/mL and TND\u2013DTG\/3TC FDC at Week 48 in SALSA. Proceedings of the Conference on Retroviruses and Opportunistic Infections, Virtual. Poster 481."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1093\/jac\/dkz347","article-title":"Switching to bictegravir\/emtricitabine\/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V\/I","volume":"74","author":"Andreatta","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/jac\/dkq544","article-title":"Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia","volume":"66","author":"Wirden","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"ofz533","DOI":"10.1093\/ofid\/ofz533","article-title":"Clinical outcomes following the use of archived proviral HIV-1 DNA genotype to guide antiretroviral therapy adjustment","volume":"7","author":"Ellis","year":"2020","journal-title":"Open. Forum Infect. Dis."},{"key":"ref_20","first-page":"2249","article-title":"Differential detection of M184V\/I between plasma historical HIV genotypes and HIV proviral DNA from PBMCs","volume":"75","author":"Margot","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e0005222","DOI":"10.1128\/cmr.00052-22","article-title":"Genotypic resistance testing of HIV-1 DNA in peripheral blood mononuclear cells","volume":"35","author":"Chu","year":"2022","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1093\/jac\/dkx233","article-title":"HIV-1 DNA ultra-deep sequencing analysis at initiation of the dual therapy dolutegravir + lamivudine in the maintenance DOLULAM pilot study","volume":"72","author":"Charpentier","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/cid\/ciy463","article-title":"Human immunodeficiency virus drug resistance: 2018 recommendations of the International Antiviral Society-USA Panel","volume":"68","author":"Calvez","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1089\/aid.2019.0111","article-title":"Week 48 resistance analyses of the once-daily, single-tablet regimen darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide (D\/C\/F\/TAF) in adults living with HIV-1 from the phase III randomized AMBER and EMERALD trials","volume":"36","author":"Lathouwers","year":"2020","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/QAI.0000000000002787","article-title":"Five years with dolutegravir plus lamivudine as a switch strategy: Much more than a positive finding","volume":"88","author":"Ciccullo","year":"2021","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ijantimicag.2019.09.002","article-title":"Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients","volume":"54","author":"Baldin","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"105893","DOI":"10.1016\/j.ijantimicag.2020.105893","article-title":"Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients","volume":"55","author":"Galizzi","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jgar.2022.07.022","article-title":"Virological efficacy of switch to DTG plus 3TC in a retrospective observational cohort of suppressed HIV-1 patients with or without past M184V: The LAMRES study","volume":"31","author":"Santoro","year":"2022","journal-title":"J. Glob. Antimicrob. Resist."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/6\/1350\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:52:32Z","timestamp":1760125952000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/6\/1350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,11]]},"references-count":28,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["v15061350"],"URL":"https:\/\/doi.org\/10.3390\/v15061350","relation":{},"ISSN":["1999-4915"],"issn-type":[{"type":"electronic","value":"1999-4915"}],"subject":[],"published":{"date-parts":[[2023,6,11]]}}}